vs
Side-by-side financial comparison of Aterian, Inc. (ATER) and CHAMPIONS ONCOLOGY, INC. (CSBR). Click either name above to swap in a different company.
Aterian, Inc. is the larger business by last-quarter revenue ($15.1M vs $15.0M, roughly 1.0× CHAMPIONS ONCOLOGY, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -52.5%, a 54.3% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -38.5%). Aterian, Inc. produced more free cash flow last quarter ($-1.0M vs $-2.0M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -13.5%).
Aterian, Inc. is a technology-enabled consumer products company that leverages artificial intelligence and data analytics to identify market demand, develop, source and distribute a wide portfolio of affordable goods spanning home improvement, wellness, personal care, pet supplies and outdoor recreation. It primarily sells its products through leading global e-commerce platforms, with core markets covering North America and Europe.
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
ATER vs CSBR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.1M | $15.0M |
| Net Profit | $-7.9M | $268.0K |
| Gross Margin | 56.1% | 51.7% |
| Operating Margin | -51.1% | 1.2% |
| Net Margin | -52.5% | 1.8% |
| Revenue YoY | -38.5% | 11.5% |
| Net Profit YoY | -512.2% | -63.2% |
| EPS (diluted) | — | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.1M | $15.0M | ||
| Q3 25 | $19.0M | $14.0M | ||
| Q2 25 | $19.5M | $12.4M | ||
| Q1 25 | $15.4M | $17.0M | ||
| Q4 24 | $24.6M | $13.5M | ||
| Q3 24 | $26.2M | $14.1M | ||
| Q2 24 | $28.0M | $14.0M | ||
| Q1 24 | $20.2M | $12.0M |
| Q4 25 | $-7.9M | $268.0K | ||
| Q3 25 | $-2.3M | $-436.0K | ||
| Q2 25 | $-4.9M | $-1.8M | ||
| Q1 25 | $-3.9M | $4.5M | ||
| Q4 24 | $-1.3M | $728.0K | ||
| Q3 24 | $-1.8M | $1.3M | ||
| Q2 24 | $-3.6M | $-109.0K | ||
| Q1 24 | $-5.2M | $-2.5M |
| Q4 25 | 56.1% | 51.7% | ||
| Q3 25 | 56.1% | 42.9% | ||
| Q2 25 | 54.3% | 41.1% | ||
| Q1 25 | 61.4% | 61.2% | ||
| Q4 24 | 63.4% | 44.9% | ||
| Q3 24 | 60.3% | 49.7% | ||
| Q2 24 | 60.4% | 48.2% | ||
| Q1 24 | 65.1% | 34.7% |
| Q4 25 | -51.1% | 1.2% | ||
| Q3 25 | -10.7% | -3.8% | ||
| Q2 25 | -23.1% | -16.2% | ||
| Q1 25 | -24.1% | 26.4% | ||
| Q4 24 | -6.5% | 5.4% | ||
| Q3 24 | -6.6% | 9.5% | ||
| Q2 24 | -11.5% | -1.9% | ||
| Q1 24 | -26.1% | -21.4% |
| Q4 25 | -52.5% | 1.8% | ||
| Q3 25 | -12.0% | -3.1% | ||
| Q2 25 | -25.0% | -14.9% | ||
| Q1 25 | -25.4% | 26.4% | ||
| Q4 24 | -5.3% | 5.4% | ||
| Q3 24 | -6.8% | 9.3% | ||
| Q2 24 | -13.0% | -0.8% | ||
| Q1 24 | -25.5% | -21.1% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | — | $0.31 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $0.09 | ||
| Q2 24 | — | $-0.01 | ||
| Q1 24 | — | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.9M | $8.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.2M | $4.2M |
| Total Assets | $29.6M | $30.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.9M | $8.5M | ||
| Q3 25 | $7.6M | $10.3M | ||
| Q2 25 | $10.5M | $9.8M | ||
| Q1 25 | $14.3M | $3.2M | ||
| Q4 24 | $18.0M | $2.8M | ||
| Q3 24 | $16.1M | $2.9M | ||
| Q2 24 | $20.3M | $2.6M | ||
| Q1 24 | $17.5M | $4.5M |
| Q4 25 | $15.2M | $4.2M | ||
| Q3 25 | $22.6M | $3.5M | ||
| Q2 25 | $24.3M | $3.8M | ||
| Q1 25 | $27.0M | $5.5M | ||
| Q4 24 | $30.0M | $681.0K | ||
| Q3 24 | $30.6M | $-332.0K | ||
| Q2 24 | $30.9M | $-1.9M | ||
| Q1 24 | $33.0M | $-2.1M |
| Q4 25 | $29.6M | $30.2M | ||
| Q3 25 | $40.1M | $30.5M | ||
| Q2 25 | $45.4M | $32.3M | ||
| Q1 25 | $49.8M | $30.6M | ||
| Q4 24 | $49.5M | $25.2M | ||
| Q3 24 | $52.1M | $24.9M | ||
| Q2 24 | $59.9M | $26.1M | ||
| Q1 24 | $55.7M | $26.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.0M | $-1.7M |
| Free Cash FlowOCF − Capex | $-1.0M | $-2.0M |
| FCF MarginFCF / Revenue | -6.9% | -13.1% |
| Capex IntensityCapex / Revenue | 0.0% | 1.6% |
| Cash ConversionOCF / Net Profit | — | -6.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | $5.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.0M | $-1.7M | ||
| Q3 25 | $-1.6M | $600.0K | ||
| Q2 25 | $-4.4M | $6.9M | ||
| Q1 25 | $-3.9M | $490.0K | ||
| Q4 24 | $-9.0K | $-283.0K | ||
| Q3 24 | $-722.0K | $311.0K | ||
| Q2 24 | $2.9M | $-1.8M | ||
| Q1 24 | $-6.0K | $-919.0K |
| Q4 25 | $-1.0M | $-2.0M | ||
| Q3 25 | $-1.6M | $554.0K | ||
| Q2 25 | $-4.4M | $6.6M | ||
| Q1 25 | — | $448.0K | ||
| Q4 24 | — | $-377.0K | ||
| Q3 24 | — | — | ||
| Q2 24 | $2.9M | $-1.8M | ||
| Q1 24 | $-42.0K | $-1.0M |
| Q4 25 | -6.9% | -13.1% | ||
| Q3 25 | -8.4% | 4.0% | ||
| Q2 25 | -22.7% | 53.5% | ||
| Q1 25 | — | 2.6% | ||
| Q4 24 | — | -2.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | 10.3% | -13.0% | ||
| Q1 24 | -0.2% | -8.4% |
| Q4 25 | 0.0% | 1.6% | ||
| Q3 25 | 0.2% | 0.3% | ||
| Q2 25 | 0.0% | 2.0% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | 0.0% | 0.7% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.2% | 0.8% |
| Q4 25 | — | -6.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | -0.39× | ||
| Q3 24 | — | 0.24× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATER
| Sales Channel Directly To Consumer | $13.1M | 87% |
| Heating Cooling And Air Quality | $2.1M | 14% |
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
